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Misonidazole and CCNU: Further evidence for a
pharmacokinetic mechanism of chemosensitization and
therapeutic gain
F.Y.F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge, UK.
Summary Detailed studies of the effects of misonidazole (MISO) on the pharmacokinetics of CCNU in the
KHT tumour, bone marrow and the gut have been carried out in order to elucidate the mechanism of
chemosensitisation by MISO, and the therapeutic gain often obtained due to the preferential enhancement of
tumour toxicity. In experiments where CCNU concentration and growth delay were both measured in the
same transplant group of tumours, we found that tumour response is well correlated with tumour peak
CCNU concentration. Further, with MISO treatment the tumour peak CCNU concentration was increased
such that the enhancement of tumour response can be entirely accounted for by this increase.
The effects of MISO on the CCNU pharmacokinetics in bone marrow and in the gut were different from
the tumour in that peak CCNU concentration was not increased. We suggest that this is the explanation for
the therapeutic gain.
Chemosensitisation of tumour cytotoxicity by nitro-
imidazole analogues such as misonidazole (MISO)
continues to be a subject of experimental and
clinical investigation. The combination of MISO or
more lipophilic nitroimidazoles with CCNU shows
particular promise (Hirst et al., 1982, 1983;
Siemann, 1981, 1982b; Siemann et al., 1983;
Workman & Twentyman, 1982; Twentyman &
Workman, 1983a). We have previously shown in
mice that MISO prolonged the initial plasma
elimination half-life of CCNU, which in turn led to
an increase in peak CCNU tumour concentration
and we proposed this as a mechanism of chemo-
sensitization for this combination (Lee &
Workman, 1983). However, more definitive
evidence for this mode of action of MISO is needed
to establish that the increase in tumour toxicity
does indeed directly parallel the increase in tumour
drug concentration. In this paper we describe
experiments to determine, using tumours from the
same transplant group, the effects of MISO on the
efficacy of CCNU against the KHT tumour
together with its effect on tu-mour CCNU concen-
tration.
The most attractive aspect of MISO chemosensi-
tisation in experimental models is that tumour
toxicity is enhanced much more than critical
normal tissues such as the bone marrow and the
small intestine. Although this "therapeutic gain"
has been found consistently, a satisfactory
explanation of the mechanism is lacking. We
showed previously that whereas MISO increased
peak tumour CCNU concentrations it had no effect
on peak plasma concentrations (Lee & Workman,
1983). We suggested further that if peak concen-
trations in critical normal tissues were likewise
unaltered, a pharmacokinetic mechanism for thera-
peutic gain would be apparent. We now present
experimental data to support this view.
Materials and methods
Drugs
All drugs used were gifts: MISO from Roche
Products Ltd.; CCNU from the Drug Synthesis and
Chemistry Branch of the National Cancer Institute,
USA, and from Lundbeck; and the monohydroxy-
lated metabolites of CCNU from Dr T.P. Johnston
of the Southern Research Institute, Alabama, USA.
Mice and tumours
All experiments were done on inbred male C3H/He
mice, supplied by Olac. KHT sarcoma was grown
in the gastrocnemius muscle as described by
Twentyman et al. (1979). Mice were treated when
tumours were between 200-400mg. The time taken
by individual tumours to reach 4 x their initial size
was calculated and growth delay was the geometric
mean of individual values in a group. Each group
contained 6-8 mice.
Drug administration
MISO was dissolved in Hanks' balance salt solution
and given i.p. in 0.04mlg-1 body wt. CCNU was
dissolved in a 1:1 mixture of ethanol/Cremphor-EL
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(Sigma) and then diluted 1:4 with saline before
injection. In all experiments mice received
2.5mmolkg-l (0.5mgg-1) MISO followed half an
hour later by an appropriate dose of CCNU.
Sample preparation and HPLC analysis
Procedures for plasma and tumour preparation
were as previously described (Lee & Workman,
1983), as was the high-performance liquid chroma-
tography (HPLC) analysis for CCNU and its meta-
bolites. In bone marrow studies, 5 mice per group
were given the appropriate treatment and, at
various time after, all the upper leg bones were then
removed. They were cleared from surrounding
muscle, washed with a jet of cold saline and dried
on tissue paper. Marrow was then expressed by
flushing through with 0.5ml cold saline using a
needle and syringe. Marrows from the same group
were pooled and syringed repeatedly to obtain a
single cell suspension. Aliquots (100pA) of the
suspension were diluted with 2% glacial acetic
acid/distilled water to lyse red blood cells, and the
remaining nucleated cells were then counted in a
haemocytometer. The rest of the cell suspension
was then homogenised with a "Verso" Laboratory
Mixer Emulsifier (Silverson, U.K.). Aliquots of
homogenates were extracted with an equal volume
of ether and processed as previously described for
tumours (Lee & Workman, 1983).
In small intestine studies, a 20cm portion of
intestine distal from the duodenum was dissected
out and washed by agitation in baths of cold saline.
The lumen was then opened, the contents removed,
and the tissue blotted on tissue paper. Preparation
of homogenates and the extraction of nitrosoureas
were the same as for tumours (Lee & Workman,
1983).
Results
KHT tumour
In order to correlate directly the effects of MISO
on tumour concentration of CCNU and the
subsequent response, both these were measured in
the same transplant group of tumours in 2 replicate
experiments.
Dose-tumour response relationshop
Figure 1 shows the effects of MISO on the response
of the KHT tumour to CCNU. As found
previously (Siemann, 1981, 1982b; Workman &
Twentyman, 1982), the effect of MISO was to shift
the dose-response curve to the left and therefore
effectively increase the apparent dose of CCNU.
The greatest effect is seen at low CCNU doses: for
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Figure 1 The effect of MISO (2.5mmolkg-1) on the
dose-response of the KHT sarcoma to CCNU. (O, A)
CCNU alone; (O, A) CCNU+MISO. Points are
geometric means for groups of 6-8 mice. Error bars
show + 1 s.e. *Error not calculated as only 4/6 mice
survived. Different symbols represent independent
experiments.
example, at 5mgkg-1 the dose-modifying factor
was - 1.5. Unusually, at the highest dose of CCNU
plus MISO only 4/6 mice survived (see Figure 1).
The effect of MISO on the acute lethality of
CCNU is generally small and deaths normally occur
only at higher CCNU doses (Workman &
Twentyman, 1982; Lee & Workman, unpublished
results).
Dose-tumour concentration relationship
We have previously shown that CCNU tumour
peak concentration occurs between 5-15min and is
relatively constant within this time (Lee &
Workman, 1983). Therefore, in this study peak
tumour concentration was taken to be the average
of concentrations at 3 time points, viz. 5, 10, and
15min. Only data on parent CCNU are presented,
since at early times the metabolite concentrations
are comparatively low.
Figure 2 shows the relationship between CCNU
dose and peak tumour concentrations of CCNU.
i lw
I I IMISO AND CCNU: A PHARMACOKINETIC MECHANISM OF ACTION 581
I-:
01 I
0)
cm
._
1
0c 0
0)
0.
E)
H
25
20
C 15-
10
5
CCNU dose (mg kg 1)
Figure 2 The effect of MISO (2.5mmolkg-1) on the
dose-tumour peak CCNU concentration relationship
in the KHT tumour. (O, A) CCNU alone; (O, A)
CCNU+MISO. Each datum point is for 12 mice.
Error bars show +1 s.e. Different symbols represent
independent experiments.
As expected peak tumour concentrations increased
with dose. MISO increased the tumour peak
CCNU concentration at each CCNU dose and
therefore shifted the concentration-dose curve to
the left.
Tumour concentration-response relationship
Figure 3 shows the plot of tumour growth delay
against peak tumour CCNU concentration. With
CCNU alone tumour response increases linearly
with increasing peak CCNU concentration up to
about 0.5 pgg-, but there is little change in growth
delay at higher concentrations. This may reflect the
presence of a resistant population. Importantly, the
data points for CCNU plus MISO clearly lie on the
same curve as those for CCNU alone. This means
that for concentrations where growth delay is
dependent on tumour peak concentration
(<0.75 gg-1) the enhancement of tumour
response by MISO can be accounted for entirely in
terms of the increase in tumour concentration.
CCNU pharmacokinetics in bone marrow and small
intestine
We have studied the effect of MISO on the
pharmacokinetics of CCNU and its hydroxylated
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Figure 3 The effect of MISO (2.5mmolkg-1) on the
peak tumour concentration-response relationship of
the KHT tumour. (O, A) CCNU alone; (0, A)
CCNU+MISO. Growth delay datum point is
geometric mean value for groups 6-8 mice. Values for
peak concentration are for 12 mice. Error bars show
+ 1 s.e. Different symbols are for independent experi-
ments. *Error not calculated as only 4/6 mice survived.
metabolites in the bone marrow and gut. Only
the data for the parent CCNU are shown in Figure
4a and 4b for the two respective normal tissues, but
the effects of MISO were similar for the meta-
bolites. It is clear that the pharmacokinetics
patterns for the two normal tissues were similar to
that seen in the plasma (Lee & Workman, 1983), in
that peak concentrations were reached rapidly
(within 2min) and the drug was then eliminated
biphasically. Furthermore the effects of MISO on
CCNU pharmacokinetics were very similar to those
seen in the plasma. It prolonged the t1/2 of the
initial elimination phase but had no effect on the
terminal phase. Significantly, in the plasma and in
the two normal tissues the peak concentrations of
CCNU were unaffected by MISO.
Discussion
We have previously shown that MISO reduced the
initial plasma clearance half-life of CCNU in mice,
resulting in a selective increase in the peak CCNU
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Figure 4 (a) The effect of MISO (2.5mmolkg 1) on the pharmacokinetics of CCNU in the mouse bone
marrow. Closed symbols (*, A, *) CCNU alone; opened symbols (O, A, Ol) CCNU+MISO. Each datum
point is for 5 mice. Different symbols represent independent experiments. (b) The effect of MISO
(2.5mmolkg 1) on the pharmacokinetics of CCNU in the mouse small intestine. (0) CCNU alone; (0)
CCNU+ MISO. Each datum point is for individual mouse. Similar results were obtained in a replicate
experiment.
concentration in the tumour without affecting the
peak concentration in the plasma (Lee &
Workman, 1983). We postulated that if in this
respect critical normal tissues behave more like the
plasma than the tumour, then this would provide a
basis for enhancement of tumour response and for
the therapeutic gain. The present findings
confirmed that MISO increases the peak tumour
CCNU concentration whereas the peak CCNU
concentrations in the two relevant critical normal
tissues studied (bone marrow and gut) were not
affected. This is due to the fact that peak tumour
concentrations lag behind the peak plasma concen-
trations, probably because of inadequate tumour
blood supply, an effect not seen in the better
perfused normal tissues. Blood flow is known to
limit tissue penetration by drugs with high permea-
bility, including the lipophilic nitrosoureas (see
Figure 5, Levin et al., 1980). The reduction in the
rate of CCNU clearance by MISO results in the
maintenance of high plasma CCNU concentrations
for a longer period, and this in turn allows the
tumour to attain a higher peak level. Thus slowing
CCNU clearance is a means of overcoming the
tumour lag effect.
We also show that the enhancement of tumour
response by MISO can be entirely accounted for by
the increase in tumour CCNU concentration. These
data are all consistent with our hypothesis that
both the chemosensitisation and the therapeutic
gain obtained with simultaneous high dose MISO
are direct consequences of its modification of
CCNU pharmacokinetics. Other evidence, though
more circumstantial, also points to the same
conclusion. For example, nitroimidazoles which are
good chemosensitizers, such as the lipophilic
analogues benznidazole and Ro 07-1902 (Workman
& Twentyman, 1982; Siemann et al., 1983;
Twentyman & Workman, 1983a) are also potent
modifiers of CCNU pharmacokinetics; conversely,
those which are inactive as chemosensitisers, such
as the hydrophilic desmethylmisonidazole and SR-
2508, are similarly inactive in modifying CCNU
pharmacokinetics (Lee & Workman, 1984).
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Furthermore, the threshold dose of MISO needed
to produce pharmacokinetic changes is the same as
that needed for chemosensitisation (Lee &
Workman, 1983).
Although our data clearly showed that tumour
cytotoxicity is well correlated with peak CCNU
concentration, it is not possible to draw any firm
conclusion regarding the relative importance of
peak concentration versus AUC in determining
toxicity. Indeed, owing to the rapid clearance of
CCNU, our estimation of the peak concentration
by taking the mean of the concentrations at 3 early
time points (5, 10 and 15min) inevitably contains
an element of AUC. For example, analysis of our
previous data (Lee & Workman, 1983) shows that
the initial a-phase, which predominates during the
first 20min, contributes 50-60% of the total plasma
AUC. Tumour concentration data are not available
for later times at lower doses, but it is likely that
the relationship between tumour response and total
AUC would be substantially the same as that found
for peak concentration (Figure 3). Nevertheless, our
present finding that MISO increases the total AUC
in bone marrow and gut while causing compara-
tively little enhancement of normal tissue toxicity
(Siemann, 1981, 1982b; Workman & Twentyman,
1982; Hirst et al., 1982) suggests that peak, or at
least early, CCNU concentrations may be more
predictive of CCNU toxicity than total AUC. This
is further supported by our observation that lipo-
philic chemosensitizers such as benznidazole and
Ro 07-1092 produce a 4-5 times greater increase in
CCNU plasma AUC than MISO (Lee & Workman,
in press) but only a disproportionally small
additional increase in normal tissue toxicity
(Workman & Twentyman, 1982; Twentyman &
Workman, 1983a; Hirst et al., 1982, 1983) which is
more likely to be due to the increase in peak level.
Some previous work has established a relation-
ship between the cytotoxicity of the nitrosoureas
and the total integrated exposure dose in vitro
(Wheeler et al., 1975, 1978) and in vivo (Levin et
al., 1979), but this is not necessarily irreconcilable
with our present proposals. Firstly, the in vitro
work used drug concentrations equivalent to those
seen in the a-phase of CCNU clearance
(>1 pgml 1), and it is quite possible that
prolonged exposure to the low concentrations seen
in the fl-phase would be comparatively ineffective
(see next paragraph). Secondly, in the in vivo work,
where rats were pretreated with phenobarbital to
increase the metabolic clearance of BCNU and so
reduce the AUC, there are no data on peak concen-
trations after i.p. administration (the route used for
determination of antitumour activity); moreover, in
contrast to the present work, only plasma, not
tumour concentrations are given. One should also
be cautious of extrapolating results from one nitro-
sourea to another. Overall, we believe that neither
peak concentration nor AUC alone is likely to be
solely responsible for the cytotoxicity of CCNU,
but that exposure during the a-phase will
predominate. One could speculate that this would
be the period during which the rate of formation of
the initial chloroethylated DNA monoadducts
would most exceed their rate of repair by the
transferase enzyme (Erickson et al., 1980).
We feel the evidence is strong that the selective
increase in tumour CCNU concentration is directly
responsible for the therapeutic gain obtained when
single high doses of MISO are combined more or
less simultaneously with CCNU. This is probably
true also for other lipophilic nitrosoureas, including
BCNU and Methyl-CCNU (Lee & Workman,
1984). There are, however, two types of evidence
which suggest that in other experimental circum-
stances different mechanisms might predominate.
Firstly, chemosensitisation has been obtained
with the nitroimidazole given some time after the
nitrosourea. For example, Siemann (personal
communication) found enhancement of tumour
response when MISO was given 3h after CCNU
and Mulcahy et al. (1981, 1982) obtained enhance-
ment when MISO or desmethylmisonidazole were
given 3 h after BCNU. It is unlikely that pharmaco-
kinetic changes could be responsible for these
effects, since nitrosourea elimination is essentially
complete by 3h. We are currently repeating these
experiments, and also including pharmacokinetic
studies. Also relevant here is our own observation
(Twentyman & Workman, 1983a) that chemosensi-
tisation would be obtained when benznidazole was
given 1 h after CCNU. Although benznidazole
could not have affected peak CCNU concentrations
we cannot exclude the possibility of a marked effect
on the tumour concentrations of the active mono-
hydroxylated metabolites. More detailed work on
this is in progress.
The second type of evidence comes from
experiments where CCNU is combined with
multiple small doses of MISO to maintain clinically
achievable plasma concentrations of about
100pgml-1. Hirst et al. (1982, 1983) reported
chemosensitisation under these conditions, and
enhancement was also obtained by Siemann
(personal communication). In contrast we found no
chemosensitisation using the same tumour and
treatment protocol (Twentyman & Workman.
1983b). As might be expected we found no
alteration in CCNU pharmacokinetics with multiple
dose MISO (Lee and Workman, unpublished) but,
since pharmacokinetic investigations were not
carried out in the studies giving positive results, we
cannot at the moment exclude this as a contri-
buting mechanism. We feel that it is likely,
however, that, as has been demonstrated for584 F.Y.F. LEE & P. WORKMAN
melphalan (Hinchcliffe et al., 1983), pharmaco-
kinetic modification will not be involved in chemo-
sensitisation with multiple low dose MISO. Cellular
mechanisms probably involving hypoxia, are likely
to predominate under these conditions (Brown,
1982; Siemann, 1982a).
We should not, however, consider the pharmaco-
kinetic mechanism of chemosensitisation and thera-
peutic gain merely as a complication seen with high
doses of lipophilic nitroimidazoles in mice, since
clinical studies with the more potent chemosensi-
tizer benznidazole have recently demonstrated
marked changes in CCNU pharmacokinetics (Lee
et al., unpublished). We originally proposed that
the ability of lipophilic nitroimidazoles to reduce
the clearance of cytotoxic drugs was due to their
inhibition of hepatic drug metabolising enzymes*
*This effect is independent of the reduction in body
temperature by high doses of lipophilic nitroimidazoles,
which can also .contribute to reduced drug clearance
(Hinchcliffe et al., 1983). As in our previous studies.(Lee
& Workman, 1983) the present work was carried out with
MISO doses which have no effect on body temperature.
(Workman et al., 1983), and recent results have
confirmed that benznidazole is a more potent
inhibitor of the hydroxylation of CCNU by liver
microsomes (Lee & Workman, unpublished). The
alteration in CCNU pharmacokinetics by benzni-
dazole has no effect on its toxicity (Roberts et al.,
1984) and it remains to be seen whether this will
contribute to an improved antitumour effect.
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